Global Oncology Companion Diagnostic Market Size Study & Forecast, by Offerings (Instrument, Consumables, Software, Services), by Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Immunohistochemistry, Other Technologies), By Disease Type (Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Others), By End-Use, and Regional Analysis, 2023-2030
Global Oncology Companion Diagnostic Market is valued at approximately USD 3.1 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 12.9% over the forecast period 2023-2030. An oncology Companion Diagnostic (CDx) is a type of medical test or biomarker that is used to identify specific characteristics or molecular alterations in a patient's tumor. These characteristics are often associated with the patient's likelihood of responding to a particular targeted therapy or treatment for cancer. The primary purpose of oncology companion diagnostics is to aid healthcare providers in making more personalized and effective treatment decisions for cancer patients. The surge in demand for targeted cancer treatment and tailored drugs, growing investments in the pharmaceutical industry, coupled with the rise in approval rate for companion diagnostics are the most prominent factors that are propelling the market demand across the globe.
Additionally, the incidence of cancer is rising worldwide, due to factors such as an aging population and unhealthy lifestyles. This is creating a greater demand for oncology companion diagnostics. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. Moreover, the increasing collaborations between diagnostic and pharma entities, as well as the growing investment in research and development activities present various lucrative opportunities over the forecast years. However, the high cost of development and testing and the regulatory challenges are hindering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Oncology Companion Diagnostic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising advancements in precision medicine, a growing development of targeted cancer therapies, as well as the growing focus of the pharmaceutical industry on targeted therapies and personalized medicine. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing number of government and healthcare industry initiatives promoting precision medicine and genomic research, coupled with ongoing advancements in diagnostic technologies and tools contribute to the development and improvement of companion diagnostics that are significantly propelling the market demand across the region.
Major market players included in this report are:
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott Laboratories
Myriad Genetics, Inc.
bioMйrieux SA
Invivoscribe, Inc.
Recent Developments in the Market:
In July 2020, The Ventana HER2 Dual ISH DNA Probe Cocktail assay received approval from the FDA as a revolutionary fast way to identify the HER2 biomarker for breast cancer and as a complementary diagnosis for Herceptin therapy.
In August 2020, The FDA approved the FoundationOne Liquid CDx, a pan-tumor liquid biopsy test, and the Guardant360 CDx assay, an NGS test that employs circulating cell-free DNA as a CDx. Both tests, Guardant360 CDx and FoundationOne Liquid CDx, serve dual purposes as companion diagnostic tests and for general tumor profiling. A companion diagnostic test provides essential information about the safe and effective use of a corresponding drug, indicating whether a patient's tumor has a genetic change targeted by a specific drug. Notably, Guardant360 CDx is approved as a companion diagnostic for osimertinib (Tagrisso), a lung cancer therapy, while FoundationOne Liquid CDx holds approval for three lung cancer therapies and a prostate cancer therapy. Ongoing clinical studies aim to support additional companion diagnostic labels for both tests.
Global Oncology Companion Diagnostic Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Offerings, Technology, Disease Type, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Offerings:
Instrument
Consumables
Software
Services
By Technology:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease Type:
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Others
By End-Use:
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Additionally, the incidence of cancer is rising worldwide, due to factors such as an aging population and unhealthy lifestyles. This is creating a greater demand for oncology companion diagnostics. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. Moreover, the increasing collaborations between diagnostic and pharma entities, as well as the growing investment in research and development activities present various lucrative opportunities over the forecast years. However, the high cost of development and testing and the regulatory challenges are hindering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Oncology Companion Diagnostic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising advancements in precision medicine, a growing development of targeted cancer therapies, as well as the growing focus of the pharmaceutical industry on targeted therapies and personalized medicine. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing number of government and healthcare industry initiatives promoting precision medicine and genomic research, coupled with ongoing advancements in diagnostic technologies and tools contribute to the development and improvement of companion diagnostics that are significantly propelling the market demand across the region.
Major market players included in this report are:
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott Laboratories
Myriad Genetics, Inc.
bioMйrieux SA
Invivoscribe, Inc.
Recent Developments in the Market:
In July 2020, The Ventana HER2 Dual ISH DNA Probe Cocktail assay received approval from the FDA as a revolutionary fast way to identify the HER2 biomarker for breast cancer and as a complementary diagnosis for Herceptin therapy.
In August 2020, The FDA approved the FoundationOne Liquid CDx, a pan-tumor liquid biopsy test, and the Guardant360 CDx assay, an NGS test that employs circulating cell-free DNA as a CDx. Both tests, Guardant360 CDx and FoundationOne Liquid CDx, serve dual purposes as companion diagnostic tests and for general tumor profiling. A companion diagnostic test provides essential information about the safe and effective use of a corresponding drug, indicating whether a patient's tumor has a genetic change targeted by a specific drug. Notably, Guardant360 CDx is approved as a companion diagnostic for osimertinib (Tagrisso), a lung cancer therapy, while FoundationOne Liquid CDx holds approval for three lung cancer therapies and a prostate cancer therapy. Ongoing clinical studies aim to support additional companion diagnostic labels for both tests.
Global Oncology Companion Diagnostic Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Offerings, Technology, Disease Type, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Offerings:
Instrument
Consumables
Software
Services
By Technology:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
Other Technologies
By Disease Type:
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Others
By End-Use:
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Oncology Companion Diagnostic Market, by Region, 2020-2030 (USD Billion)
1.2.2. Oncology Companion Diagnostic Market, by Offerings, 2020-2030 (USD Billion)
1.2.3. Oncology Companion Diagnostic Market, by Technology, 2020-2030 (USD Billion)
1.2.4. Oncology Companion Diagnostic Market, by Disease Type, 2020-2030 (USD Billion)
1.2.5. Oncology Companion Diagnostic Market, by End-use, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET DYNAMICS
3.1. Oncology Companion Diagnostic Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Surge in demand for targeted cancer treatment and tailored drugs
3.1.1.2. Rising incidence of cancer
3.1.2. Market Challenges
3.1.2.1. High cost of development and testing
3.1.2.2. Regulatory challenges
3.1.3. Market Opportunities
3.1.3.1. Increasing collaborations between diagnostic and pharma entities
3.1.3.2. Growing investment in the research and development activities
CHAPTER 4. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY OFFERINGS
5.1. Market Snapshot
5.2. Global Oncology Companion Diagnostic Market by Offerings, Performance - Potential Analysis
5.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Offerings 2020-2030 (USD Billion)
5.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
5.4.1. Instrument
5.4.2. Consumables
5.4.3. Software
5.4.4. Services
CHAPTER 6. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY TECHNOLOGY
6.1. Market Snapshot
6.2. Global Oncology Companion Diagnostic Market by Technology, Performance - Potential Analysis
6.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
6.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Next-Generation Sequencing (NGS)
6.4.3. Immunohistochemistry (IHC)
6.4.4. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
6.4.5. Other Technologies
CHAPTER 7. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY DISEASE TYPE
7.1. Market Snapshot
7.2. Global Oncology Companion Diagnostic Market by Disease Type, Performance - Potential Analysis
7.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
7.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
7.4.1. Breast cancer
7.4.2. Non-small cell lung cancer
7.4.3. Colorectal cancer
7.4.4. Leukemia
7.4.5. Melanoma
7.4.6. Prostate cancer
7.4.7. Others
CHAPTER 8. ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY END-USE
8.1. Market Snapshot
8.2. Global Oncology Companion Diagnostic Market by End-use, Performance - Potential Analysis
8.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
8.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
8.4.1. Hospital
8.4.2. Pathology/Diagnostic laboratory
8.4.3. Academic medical center
CHAPTER 9. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, REGIONAL ANALYSIS
9.1. Top Leading Countries
9.2. Top Emerging Countries
9.3. Oncology Companion Diagnostic Market, Regional Market Snapshot
9.4. North America Oncology Companion Diagnostic Market
9.4.1. U.S. Oncology Companion Diagnostic Market
9.4.1.1. Offerings breakdown estimates & forecasts, 2020-2030
9.4.1.2. Technology breakdown estimates & forecasts, 2020-2030
9.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
9.4.1.4. End-use breakdown estimates & forecasts, 2020-2030
9.4.2. Canada Oncology Companion Diagnostic Market
9.5. Europe Oncology Companion Diagnostic Market Snapshot
9.5.1. U.K. Oncology Companion Diagnostic Market
9.5.2. Germany Oncology Companion Diagnostic Market
9.5.3. France Oncology Companion Diagnostic Market
9.5.4. Spain Oncology Companion Diagnostic Market
9.5.5. Italy Oncology Companion Diagnostic Market
9.5.6. Rest of Europe Oncology Companion Diagnostic Market
9.6. Asia-Pacific Oncology Companion Diagnostic Market Snapshot
9.6.1. China Oncology Companion Diagnostic Market
9.6.2. India Oncology Companion Diagnostic Market
9.6.3. Japan Oncology Companion Diagnostic Market
9.6.4. Australia Oncology Companion Diagnostic Market
9.6.5. South Korea Oncology Companion Diagnostic Market
9.6.6. Rest of Asia Pacific Oncology Companion Diagnostic Market
9.7. Latin America Oncology Companion Diagnostic Market Snapshot
9.7.1. Brazil Oncology Companion Diagnostic Market
9.7.2. Mexico Oncology Companion Diagnostic Market
9.8. Middle East & Africa Oncology Companion Diagnostic Market
9.8.1. Saudi Arabia Oncology Companion Diagnostic Market
9.8.2. South Africa Oncology Companion Diagnostic Market
9.8.3. Rest of Middle East & Africa Oncology Companion Diagnostic Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Agilent Technologies, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Recent Developments
10.3.2. Illumina, Inc.
10.3.3. QIAGEN N.V.
10.3.4. Thermo Fisher Scientific, Inc.
10.3.5. F. Hoffmann-La Roche Ltd.
10.3.6. ARUP Laboratories
10.3.7. Abbott Laboratories
10.3.8. Myriad Genetics, Inc.
10.3.9. bioMйrieux SA
10.3.10. Invivoscribe, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Oncology Companion Diagnostic Market, by Region, 2020-2030 (USD Billion)
1.2.2. Oncology Companion Diagnostic Market, by Offerings, 2020-2030 (USD Billion)
1.2.3. Oncology Companion Diagnostic Market, by Technology, 2020-2030 (USD Billion)
1.2.4. Oncology Companion Diagnostic Market, by Disease Type, 2020-2030 (USD Billion)
1.2.5. Oncology Companion Diagnostic Market, by End-use, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET DYNAMICS
3.1. Oncology Companion Diagnostic Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Surge in demand for targeted cancer treatment and tailored drugs
3.1.1.2. Rising incidence of cancer
3.1.2. Market Challenges
3.1.2.1. High cost of development and testing
3.1.2.2. Regulatory challenges
3.1.3. Market Opportunities
3.1.3.1. Increasing collaborations between diagnostic and pharma entities
3.1.3.2. Growing investment in the research and development activities
CHAPTER 4. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY OFFERINGS
5.1. Market Snapshot
5.2. Global Oncology Companion Diagnostic Market by Offerings, Performance - Potential Analysis
5.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Offerings 2020-2030 (USD Billion)
5.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
5.4.1. Instrument
5.4.2. Consumables
5.4.3. Software
5.4.4. Services
CHAPTER 6. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY TECHNOLOGY
6.1. Market Snapshot
6.2. Global Oncology Companion Diagnostic Market by Technology, Performance - Potential Analysis
6.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
6.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Next-Generation Sequencing (NGS)
6.4.3. Immunohistochemistry (IHC)
6.4.4. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
6.4.5. Other Technologies
CHAPTER 7. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY DISEASE TYPE
7.1. Market Snapshot
7.2. Global Oncology Companion Diagnostic Market by Disease Type, Performance - Potential Analysis
7.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Disease Type 2020-2030 (USD Billion)
7.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
7.4.1. Breast cancer
7.4.2. Non-small cell lung cancer
7.4.3. Colorectal cancer
7.4.4. Leukemia
7.4.5. Melanoma
7.4.6. Prostate cancer
7.4.7. Others
CHAPTER 8. ONCOLOGY COMPANION DIAGNOSTIC MARKET, BY END-USE
8.1. Market Snapshot
8.2. Global Oncology Companion Diagnostic Market by End-use, Performance - Potential Analysis
8.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
8.4. Oncology Companion Diagnostic Market, Sub Segment Analysis
8.4.1. Hospital
8.4.2. Pathology/Diagnostic laboratory
8.4.3. Academic medical center
CHAPTER 9. GLOBAL ONCOLOGY COMPANION DIAGNOSTIC MARKET, REGIONAL ANALYSIS
9.1. Top Leading Countries
9.2. Top Emerging Countries
9.3. Oncology Companion Diagnostic Market, Regional Market Snapshot
9.4. North America Oncology Companion Diagnostic Market
9.4.1. U.S. Oncology Companion Diagnostic Market
9.4.1.1. Offerings breakdown estimates & forecasts, 2020-2030
9.4.1.2. Technology breakdown estimates & forecasts, 2020-2030
9.4.1.3. Disease Type breakdown estimates & forecasts, 2020-2030
9.4.1.4. End-use breakdown estimates & forecasts, 2020-2030
9.4.2. Canada Oncology Companion Diagnostic Market
9.5. Europe Oncology Companion Diagnostic Market Snapshot
9.5.1. U.K. Oncology Companion Diagnostic Market
9.5.2. Germany Oncology Companion Diagnostic Market
9.5.3. France Oncology Companion Diagnostic Market
9.5.4. Spain Oncology Companion Diagnostic Market
9.5.5. Italy Oncology Companion Diagnostic Market
9.5.6. Rest of Europe Oncology Companion Diagnostic Market
9.6. Asia-Pacific Oncology Companion Diagnostic Market Snapshot
9.6.1. China Oncology Companion Diagnostic Market
9.6.2. India Oncology Companion Diagnostic Market
9.6.3. Japan Oncology Companion Diagnostic Market
9.6.4. Australia Oncology Companion Diagnostic Market
9.6.5. South Korea Oncology Companion Diagnostic Market
9.6.6. Rest of Asia Pacific Oncology Companion Diagnostic Market
9.7. Latin America Oncology Companion Diagnostic Market Snapshot
9.7.1. Brazil Oncology Companion Diagnostic Market
9.7.2. Mexico Oncology Companion Diagnostic Market
9.8. Middle East & Africa Oncology Companion Diagnostic Market
9.8.1. Saudi Arabia Oncology Companion Diagnostic Market
9.8.2. South Africa Oncology Companion Diagnostic Market
9.8.3. Rest of Middle East & Africa Oncology Companion Diagnostic Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Company
10.1.2. Company
10.1.3. Company
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Agilent Technologies, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Recent Developments
10.3.2. Illumina, Inc.
10.3.3. QIAGEN N.V.
10.3.4. Thermo Fisher Scientific, Inc.
10.3.5. F. Hoffmann-La Roche Ltd.
10.3.6. ARUP Laboratories
10.3.7. Abbott Laboratories
10.3.8. Myriad Genetics, Inc.
10.3.9. bioMйrieux SA
10.3.10. Invivoscribe, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Oncology Companion Diagnostic Market, report scope
TABLE 2. Global Oncology Companion Diagnostic Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Oncology Companion Diagnostic Market estimates & forecasts by Offerings 2020-2030 (USD Billion)
TABLE 4. Global Oncology Companion Diagnostic Market estimates & forecasts by Technology 2020-2030 (USD Billion)
TABLE 5. Global Oncology Companion Diagnostic Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
TABLE 6. Global Oncology Companion Diagnostic Market estimates & forecasts by End-use 2020-2030 (USD Billion)
TABLE 7. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 18. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 21. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 24. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 27. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 30. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 33. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 36. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 39. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 42. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 45. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 48. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 51. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 54. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 57. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 60. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 63. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 66. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. Saudi Arabia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 69. South Africa Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. RoMEA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 71. List of secondary sources, used in the study of global Oncology Companion Diagnostic Market
TABLE 72. List of primary sources, used in the study of global Oncology Companion Diagnostic Market
TABLE 73. Years considered for the study
TABLE 74. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Oncology Companion Diagnostic Market, report scope
TABLE 2. Global Oncology Companion Diagnostic Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Oncology Companion Diagnostic Market estimates & forecasts by Offerings 2020-2030 (USD Billion)
TABLE 4. Global Oncology Companion Diagnostic Market estimates & forecasts by Technology 2020-2030 (USD Billion)
TABLE 5. Global Oncology Companion Diagnostic Market estimates & forecasts by Disease Type 2020-2030 (USD Billion)
TABLE 6. Global Oncology Companion Diagnostic Market estimates & forecasts by End-use 2020-2030 (USD Billion)
TABLE 7. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Oncology Companion Diagnostic Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. Global Oncology Companion Diagnostic Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 18. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. U.S. Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. Canada Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 21. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. Canada Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. UK Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 24. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. UK Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. Germany Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 27. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. Germany Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. France Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 30. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. France Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Italy Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 33. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Italy Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. Spain Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 36. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. Spain Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. RoE Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 39. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. RoE Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. China Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 42. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. China Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. India Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 45. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. India Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. Japan Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 48. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. Japan Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. South Korea Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 51. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. South Korea Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. Australia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 54. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. Australia Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 57. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. RoAPAC Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Brazil Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 60. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Brazil Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. Mexico Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 63. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. Mexico Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. RoLA Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 66. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. RoLA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. Saudi Arabia Oncology Companion Diagnostic Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 69. South Africa Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. RoMEA Oncology Companion Diagnostic Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 71. List of secondary sources, used in the study of global Oncology Companion Diagnostic Market
TABLE 72. List of primary sources, used in the study of global Oncology Companion Diagnostic Market
TABLE 73. Years considered for the study
TABLE 74. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Oncology Companion Diagnostic Market, research methodology
FIG 2. Global Oncology Companion Diagnostic Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Companion Diagnostic Market, key trends 2022
FIG 5. Global Oncology Companion Diagnostic Market, growth prospects 2023-2030
FIG 6. Global Oncology Companion Diagnostic Market, porters 5 force model
FIG 7. Global Oncology Companion Diagnostic Market, pest analysis
FIG 8. Global Oncology Companion Diagnostic Market, value chain analysis
FIG 9. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Oncology Companion Diagnostic Market, regional snapshot 2020 & 2030
FIG 15. North America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 16. Europe Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Oncology Companion Diagnostic Market, research methodology
FIG 2. Global Oncology Companion Diagnostic Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Companion Diagnostic Market, key trends 2022
FIG 5. Global Oncology Companion Diagnostic Market, growth prospects 2023-2030
FIG 6. Global Oncology Companion Diagnostic Market, porters 5 force model
FIG 7. Global Oncology Companion Diagnostic Market, pest analysis
FIG 8. Global Oncology Companion Diagnostic Market, value chain analysis
FIG 9. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Oncology Companion Diagnostic Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Oncology Companion Diagnostic Market, regional snapshot 2020 & 2030
FIG 15. North America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 16. Europe Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Oncology Companion Diagnostic Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
